These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 16372535)

  • 1. Enzastaurin and pemetrexed exert synergistic antitumor activity in thyroid cancer cell lines in vitro.
    Oberschmidt O; Eismann U; Schulz L; Struck S; Blatter J; Lahn MM; Ma D; Hanauske AR
    Int J Clin Pharmacol Ther; 2005 Dec; 43(12):603-4. PubMed ID: 16372535
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells.
    Tekle C; Giovannetti E; Sigmond J; Graff JR; Smid K; Peters GJ
    Br J Cancer; 2008 Sep; 99(5):750-9. PubMed ID: 18728666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pemetrexed, a multitargeted antifolate drug, demonstrates lower efficacy in comparison to methotrexate against osteosarcoma cell lines.
    Bodmer N; Walters DK; Fuchs B
    Pediatr Blood Cancer; 2008 Apr; 50(4):905-8. PubMed ID: 17534933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical potency of methotrexate, aminopterin, talotrexin and pemetrexed in childhood leukemias.
    Norris RE; Adamson PC
    Cancer Chemother Pharmacol; 2010 May; 65(6):1125-30. PubMed ID: 19784838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Schedule-dependent synergism and antagonism between pemetrexed and paclitaxel in human carcinoma cell lines in vitro.
    Kano Y; Akutsu M; Tsunoda S; Izumi T; Mori K; Fujii H; Yazawa Y; Mano H; Furukawa Y
    Cancer Chemother Pharmacol; 2004 Dec; 54(6):505-13. PubMed ID: 15340759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514.
    Worzalla JF; Shih C; Schultz RM
    Anticancer Res; 1998; 18(5A):3235-9. PubMed ID: 9858888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of pemetrexed disodium (ALIMTA, multitargeted antifolate) and irradiation in vitro.
    Bischof M; Weber KJ; Blatter J; Wannenmacher M; Latz D
    Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1381-8. PubMed ID: 11955753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Folic acid antagonists pemetrexed].
    Heinzl S
    Med Monatsschr Pharm; 2004 Jul; 27(7):220-2. PubMed ID: 15296355
    [No Abstract]   [Full Text] [Related]  

  • 9. Pemetrexed: mRNA expression of the target genes TS, GARFT and DHFR correlates with the in vitro chemosensitivity of human solid tumors.
    Eismann U; Oberschmidt O; Ehnert M; Fleeth J; Lüdtke FE; Struck S; Schulz L; Blatter J; Lahn MM; Ma D; Niyikiza C; Paoletti P; Hanauske AR
    Int J Clin Pharmacol Ther; 2005 Dec; 43(12):567-9. PubMed ID: 16372519
    [No Abstract]   [Full Text] [Related]  

  • 10. Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells.
    Lee KW; Kim SG; Kim HP; Kwon E; You J; Choi HJ; Park JH; Kang BC; Im SA; Kim TY; Kim WH; Bang YJ
    Cancer Res; 2008 Mar; 68(6):1916-26. PubMed ID: 18339873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents.
    Calvert H
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):3-10. PubMed ID: 10598549
    [No Abstract]   [Full Text] [Related]  

  • 12. Enzastaurin.
    Ma S; Rosen ST
    Curr Opin Oncol; 2007 Nov; 19(6):590-5. PubMed ID: 17906457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis.
    Zhao R; Zhang S; Hanscom M; Chattopadhyay S; Goldman ID
    Clin Cancer Res; 2005 Feb; 11(3):1294-301. PubMed ID: 15709201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy.
    Villela LR; Stanford BL; Shah SR
    Pharmacotherapy; 2006 May; 26(5):641-54. PubMed ID: 16637794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant erythropoietin differently affects proliferation of mesothelioma cells but not sensitivity to cisplatin and pemetrexed.
    Palumbo C; Battisti S; Carbone D; Albonici L; Alimandi M; Bei R; Modesti A
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):893-901. PubMed ID: 17922127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a folate transporter in HeLa cells with a low pH optimum and high affinity for pemetrexed distinct from the reduced folate carrier.
    Wang Y; Zhao R; Goldman ID
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6256-64. PubMed ID: 15448015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow.
    Das JR; Fryar-Tita EB; Green S; Southerland WM; Bowen D
    Anticancer Res; 2007; 27(2):825-33. PubMed ID: 17465208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical evaluation of pemetrexed in pediatric solid tumors.
    Norris RE; Rappaport EF; Adamson PC
    Pediatr Blood Cancer; 2011 Dec; 57(7):1233-5. PubMed ID: 21850675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antifolates: the next millennium.
    Allegra CJ
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):1-2. PubMed ID: 10598548
    [No Abstract]   [Full Text] [Related]  

  • 20. Glutamyl hydrolase: properties and pharmacologic impact.
    Galivan J; Ryan T; Rhee M; Yao R; Chave K
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):33-7. PubMed ID: 10598552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.